News & Stories
See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.
CMT Research Foundation Targets CMT1X in Partnership with University of Illinois Chicago
CMTRF’s 11th Major Project in Less Than Three Years ATLANTA (July 8, 2021) The CMT Research Foundation, a nonprofit focused solely on delivering treatments and cures for Charcot-Marie-Tooth, today announced it has partnered with the University of Illinois Chicago...
CMT Research Foundation Targets CMT1X in Partnership with University of Illinois Chicago
The CMT Research Foundation is partnering with the University of Illinois Chicago to test a potential therapeutic for CMT1X, the second most common form of CMT, behind only CMT1A in prevalence. CMT is one of the most common inherited neurological disorders, affecting...
CMT Research Foundation To Host First Global Research Convention
Several Hundred Charcot-Marie-Tooth* World Leaders Gather to Accelerate Collaboration and Advancements in Research; Pharma Partner DTx to Review Significant Progress in Drug Delivery Gene Therapy Innovator and Pioneer Dr. James M. Wilson to Keynote ATLANTA (June...
Be the Change We Wish to See: Join the Spring CMT Research Challenge
Tired of living with a disease that has no treatments and cures, Chelsea Layton and her fellow CMT Research Foundation volunteer ambassadors created the Spring CMT Research Challenge to rally the CMT community to help speed drug development and answers. Learn more and join the challenge.
Promising Research Results Point to Potential Cures for Two Most Common Forms of CMT
Momentum is building in the development of gene therapies for Charcot-Marie-Tooth disease. Landmark back-to-back research publications offer innovative approaches to potentially curing the two most common forms of CMT. Here is what the findings showed and what they mean for CMT patients and families.
Biopharma Leader Joseph Mulvey Joins CMT Research Foundation Board of Directors to Help Deliver Treatments & Cures
The CMT Research Foundation is pleased to announce that Joseph Mulvey, MBA, PMP, has joined its board of directors. Joe is the founder and president of biopharmaceutical consulting firm Ealaín Technology Solutions (ETS), which provides project management, process design and finance solutions to the biopharma industry. Joe will bring his extensive knowledge and experience in the biopharma arena to help advance research, treatments and cures for CMT.
7 Ideas for Personal Fundraising Success
CMT patient Chelsea Layton shares her tips and ideas for starting a personal fundraiser.
Turning $128,000 into Millions to Deliver a Treatment for CMT
If you’ve ever been frustrated by the slow pace of research progress or questioned how a single donation makes a difference, the collaboration between the CMT Research Foundation and DTx Pharma proves that one simple action, one bold move and one donation is all it...
Losing My Independence is Not Rare to Me
When I was diagnosed with CMT at age 2, it wasn’t a surprise to anyone. I was the seventh person in my family to be born with the disease. Although we were familiar with CMT, we couldn’t understand why the disease was progressing faster in me than anyone else in our family. Read Monica’s story.
Living in Pain Every Day is Not Rare to Me
The day after my 29th birthday, I received confirmation that the intense pain I’d been experiencing all my life was most certainly not in my head. It was Charcot-Marie-Tooth 1X. During the first year after my diagnosis, I fell into a deep depression. My family had a hard time accepting this diagnosis. Telling my story has changed my life, and I’m determined to change the future. Read more.
Important Research News Announcements
- Genomic Studies in Charcot-Marie-Tooth Disease July 31, 2024
- Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives March 5, 2024
- Accelerate Clinical Trials in CMT (ACTCMT) Study March 1, 2024
- Creation of a Schwann Cell Gene Regulatory Network February 29, 2024
- Activation of XBP1s attenuates disease severity in models of proteotoxic Charcot-Marie-Tooth type 1B [Preprint] February 2, 2024
NEWSLETTER SIGNUP
Stay up to date on new CMT research, treatments and clinical trials
Address
4062 Peachtree Road
Suite A209
Atlanta, GA 30319
Phone Number
404.806.7180
Media Inquiries
© 2024 CMT Research Foundation | Privacy Policy